This clinical trial, sponsored by Stanford University, investigates the safety and feasibility of autologous CD22 CAR T cell therapy administered after commercial CD19 CAR T cell therapy (Tisagenlecleucel) in pediatric and young adult patients with relapsed or refractory B-cell malignancies. The trial targets a niche but critical segment of the oncology market, particularly in pediatric leukemia, where there is a significant unmet need for effective therapies following initial CAR T cell treatments. Given the increasing prevalence of CAR T therapies and the potential for combination strategies, this trial could position Stanford as a leader in advancing CAR T cell therapies, potentially enhancing its competitive edge against other institutions and biopharmaceutical companies in the CAR T space. The successful outcomes could lead to expanded indications for CAR T therapies and increased market share for related products.